Biomanufacturing Technology and Partnership (BioTAP) FI supports Singapore public-sector researchers developing biomanufacturing processes and analytical capabilities for GMP readiness and industry adoption.
Funder: Agency for Science Technology and Research
Due Dates: January 8, 2027, 5:00pm Singapore time (Submission) | At least seven days before submission (Eligibility waiver requests)
Funding Amounts: Seed: up to S$500,000 for 12–18 months | Core: up to S$5 million for three years; caps include overheads
Summary: Supports Singapore public-sector research advancing biomanufacturing processes, analytical capabilities and CMC know-how towards GMP readiness and industry adoption.
Key Information: Lead PIs need at least a 0.7 FTE primary appointment at an eligible Singapore institution; institutional submission quotas apply.
The Biomanufacturing Technology and Partnership (BioTAP) Funding Initiative is an RIE2030 initiative implemented by A*STAR to strengthen Singapore’s biopharma manufacturing competitiveness across conventional and emerging therapeutic modalities. It connects public-sector research with industry needs, supporting process optimisation, digitalisation, sustainability, manufacturing readiness and novel technology platforms.
The first call, Accelerate Translation & GMP Readiness, supports pre-GMP process development and piloting, and Chemistry, Manufacturing and Controls (CMC) know-how and analytical capability development. It seeks robust, scalable processes, manufacturing-relevant demonstrations, product characterisation methods and reusable capabilities that reduce translational risks. Related capability gaps beyond the illustrative activities may also be considered. The emphasis is on evidence supporting subsequent GMP implementation, clinical development and industry adoption, rather than requiring GMP execution itself.